Cure My Disease

Don't miss your cure!

 Log in / Sign up

Marijuana's brain impact in HIV patients under the microscope

NCT ID NCT04810858

Knowledge-focused Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how chronic marijuana use changes brain inflammation and thinking abilities in people with HIV. Researchers will use brain scans and blood tests to measure brain health in 220 adults. The goal is to understand the effects, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 59 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * verified HIV status * Current marijuana use (MJ+ groups only) * No current marijuana use (MJ- groups only) * current engagement in HIV care (HIV+ participants only) * receipt of cART as first-line of treatment (HIV+ participants only) * stable cART regimen (HIV+ participants only) * undetectable HIV RNA viral load for \>1 year (HIV+ participants only) Exclusion Criteria: * Lifetime abuse for any illicit drug other than marijuana * \<9th grade education; illiteracy or lack of fluency in English * history of moderate or severe head trauma * unstable or serious neurological disorders * severe mental illness * systemic autoimmune diseases * immunotherapy * MRI contraindications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence cognitive disorder HIV infectious disease Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis Cognition HIV Inflammation Neuroimaging

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Biotech Place

    RECRUITING

    Winston-Salem, North Carolina, 27101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.